Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of CC-93538 in Eosinophilic Esophagitis
NCT04991935Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of cendakimab in eosinophilic esophagitis (EoE), sponsored by Celgene Corporation. Started Aug 2022; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04991935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991935.